PureTech Health (PRTC) 44th Annual J.P. Morgan Healthcare Conference summary

Business model and strategy

• Operates a hub-and-spoke model, spinning out programs into standalone entities to advance therapies and generate financial returns.

• Focuses on de-risked drug development by targeting validated pharmacology and high unmet medical needs.

• Portfolio approach enables risk balancing and efficient capital allocation, with no bias toward continuing underperforming programs.

• Retains equity and non-dilutive economics (royalties, milestones) in spun-out entities, ensuring multiple value streams.

• Emphasizes continuous innovation, particularly in small molecules and CNS, leveraging prior success and expertise.

Clinical and financial achievements

• Achieved 80% clinical trial success rate and three FDA-approved treatments, including Cobenfy for schizophrenia.

• Cobenfy generated over $1.1 billion in gross returns from an $18.5 million investment, with ongoing royalties and milestones valued at ~$300 million through 2033.

• Seaport Therapeutics spun out, raising $325 million, with PureTech retaining a 35% stake and non-dilutive economics.

• Self-funded for eight years, maintaining a $320 million balance sheet as of 2025 H1.

Pipeline and upcoming milestones

• Celea Therapeutics is advancing deupirfenidone, a next-gen antifibrotic for IPF, showing significant efficacy in phase II-B and moving to phase III.

• Gallop Oncology is developing LYT-200, a novel antibody for AML, showing median overall survival of 13.2 months in phase I, surpassing benchmarks.

• Seaport Therapeutics has three candidates, two in clinical stage for major depressive and generalized anxiety disorders.

• Operational priorities for 2026 include securing funding for Gallop and Celea, initiating pivotal trials, and spinning out these programs.